CoV-2 virus protein protects mice against many of the most severe effects of the disease, including some that can linger on.

Researchers have shown a new drug compound can prevent long COVID symptoms in mice—a landmark finding that could lead to a ...

Australian scientists developed a novel antiviral that targets the SARS-CoV-2 PLpro enzyme, showing strong preclinical efficacy in reducing both acute and long COVID symptoms in mice.

Our study on the spike-fibrinogen interaction reveals a novel immune escape strategy of SARS-CoV-2, with potential implications for disease severity and treatment. By binding fibrinogen, the virus not ...

completing early-stage clinical trials would mean reducing the time to get the treatment approved if SARS-CoV-2 evolves and ...

Yeda Research and Development Co. Ltd. has divulged broad-spectrum coronavirus entry inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19), SARS-CoV infection and ...

The following is a summary of “A viro-immunological model to characterize the antiviral effect of molnupiravir in ...

New research links multisystem inflammatory syndrome in children with COVID-19 to Epstein-Barr virus reactivation, revealing ...

SARS originated in Guangdong province , southern China and by the time it had been brought … Severe Acute Respiratory Syndrome (SARS) is a disease that first appeared in humans in November 2002.

Spike proteins are critical for SARS-CoV-2 to enter human cells ... can prevent long COVID symptoms in mice – a landmark finding that could lead to a future treatment for the debilitating condition.